Akshat Jain/Photo:
lluh.org
Apr 22, 2026, 07:40
Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn:
”It was wonderful presenting our research on factor prophylaxis for Children with Von Willebrand Disease at the WFH 2026 congress.
How we treat VWD especially in young children remain undetermined in the absence of robust clinical trials and medications that always are late to arrive for pediatric indications.
Through the WIL33 study (7 country, 3 continents ) that I had the honor to lead for Octapharma this gap has been addressed and real world care can start to be defined to assist clinicians world over.”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care